Age (y) | 59 | 57 | 73 | 72 | 73 | 56 |
Initial PSA level (ng/mL) | 111.1 | 5.7 | 27.0 | 30.6 | 9.6 | 76.3 |
Prostate biopsy | | | | | | |
Gleason score | 4 + 3 = 7b | 3 + 4 = 7a | 3 + 4 = 7a | 4 + 3 = 7b | 3 + 4 = 7a | 8 |
Cancer location | R < L | R > L | R = L | L only | R > L | R = L |
Number of positive cores | 6/10 | 5/8 | 5/6 | 3/12 | 7/10 | 11/11 |
Clinical stage | cT2c (L lobe) | cT2a (R base) | cT1 | cT1 | cT2c (bilateral) | cT2c (both lobes) |
TRUS suggestive of cancer | L lobe | R base | Normal | Normal | R base | Both lobes |
TRUS prostate volume (cm3) | 36 | 40 | 36 | 39 | 17 | 49 |
Staging | | | | | | |
Bone scan indication | Not done (PSMA PET) | Routine scan | PSA elevation | Not done (PSMA PET) | Routine scan | Not done (PSMA PET) |
Bone scan result | | L os ilium lesion | Exclusion of mets | | L3 lesion | |
68Ga-PSMA PET indication | Exclusion of mets | Suggestive bone scan | Exclusion of mets | Exclusion of mets | Exclusion of mets | Exclusion of mets |
68Ga-PSMA PET result | Parailiac LN mets | Equivocal* | No lesions | No lesions | No lesions | LN mets† |
RPE | | | | | | |
Prostate volume (cm3) | 48 | 34 | 40 | 52 | 30 | 51 |
Cancer volume (cm3) | 20.9 | 2.6 | 5.7 | 14.5 | 7.8 | 30.2 |
Cancer involvement | 43.5% | 7.8% | 14.6% | 27.9% | 26.5% | 59.2% |
Gleason score | 4 + 3 = 7b | 3 + 4 = 7a | 4 + 3 = 7b | 4 + 3 = 7b | 4 + 5 = 9a | 4 + 5 = 9a |
Positive surgical margin | L apex | No | R anterior | L seminal vesicle | No | L posterior |
Seminal vesicle invasion | Both | L | No | L | Both | Both |
Pathologic stage | pT3b pN1 | pT3b pN0 | pT3a pN0 | pT3b pN1 | pT3b pN0 | pT3b N1 |